Reason I've posted this is to illustrate that drug administering via skin patches has been around since 1979--over THIRTY YEARS AGO--and for 3M and Glaxo to have been conducting ongoing trials with OBJ and now just re-committed to further research must surely mean one thing....OBJ must have an outstanding product!!
Don't forget that their technology has also passed clinical trials with Azropharm (?) Laboratories in the US and some mention has been made of possibly a THIRD multi-national pharma taking an interest.
As far as "peeling the skin back" when using the OBJ patch to administer a drug, that's a furphy, and the reason an EM field is installed in their patch is to help force through larger molecules or peptides into the circulatory system by slightly enlarging the skin pores.
As we've said before, 3M, Glaxo and the X factor wouldn't be wasting their time and money with OBJ, out of the myriad of companies that have experience in this field, unless they thought they were onto something special that could fulfil the much-needed requirements of modernising transdermal drug administration.
Read and enjoy.
All the very best, chick
OBJ Price at posting:
4.7¢ Sentiment: Hold Disclosure: Held